Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 268

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 268
---
 Rewell, MultiplAI, and Heritas. On August 28, 2023, representatives of OmnigenicsAI and MultiplAI had a meeting with Linklaters LLP (“Linklaters”) to discuss a potential business combination with APx and the MultiplAI Acquisition and began negotiations to formally engage Linklaters as its external legal counsel to assist it in a potential share purchase agreement in respect of the MultiplAI Acquisition and business combination transaction with APx. The engagement letter was executed on September 18, 2023. 124 The shareholder vote for APx was set for September 1, 2023 to vote on the purchase agreement of Sponsor and APx. On September 8, 2023, following the termination of discussions with potential target PG, APx entered into a purchase agreement with the Initial Sponsor and the Sponsor, whereby the Initial Sponsor agreed to transfer to the Sponsor 3,342,188 Founder Shares and 6,936,250 Private Placement Warrants (collectively, the “Transferred Equity”) purchased at the time of APx’s IPO pursuant to a Private Placement Warrants Purchase Agreement, dated December 6, 2021. As consideration for the transfer, the Sponsor paid $1 for such Transferred Equity, and committed to pay up to $50,000 in expense related to APx’s regulatory filings. The Initial Sponsor retained 970,312 Founder Shares and 2,013,750 Private Placement Warrants, which equity was not a component of the Transferred Equity. The transfer and all agreements executed in connection with the transfer (including the transactions contemplated therein) are referred to as the “Sponsor Alliance.” In connection with the Sponsor Alliance, APx, its officers and directors, the Initial Sponsor and the Sponsor entered into additional agreements whereby: (i) the Sponsor signed a joinder agreement to become a party to the letter agreement and the registration rights agreement, both dated December 6, 2021 and entered into in connection with the IPO, among APx, the Initial Sponsor and certain other shareholders of APx; and (ii) the letter agreement was amended by the parties thereto to add a section to not restrict the transfer of founder shares and private placement warrants in connection with the purchase agreement. On October 30, 2023, the Parent sent the first draft of the share purchase agreement for MultiplAI’s review. On November 1, Linklaters started the due diligence process for MultiplAI. On November 9,